Our preliminary data indicate that VPAC2 antagonists can be used to decrease lung pathology caused by whooping cough, indicating that the use of this axis for the development of immunotherapies can be applied to attenuate infection caused by Bordetella spp. This evidence concerns the gene VIPR2 and infection.